Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02776761 · ClinicalTrials.gov registry record · Phase 1
A Single-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Hantaan Puumala Virus DNA Vaccine
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT02776761 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 27 participants.
The verdict
NCT02776761, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is a single-center, randomized, single-blinded study of the Hantaan virus HTNV DNA vaccine alone, Puumala virus PUUV DNA vaccine alone, and mixed Hantaan/Puumala HTNV/PUUV DNA vaccines delivered intramuscularly IM by the needle-free PharmaJet Stratus DSJI device.
Interventions
- BIOLOGICAL Hantaan Vaccine:
- BIOLOGICAL Puumala Vaccine
- BIOLOGICAL Hantaan/Puumala Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2016-08-30 |
| Est. Completion | 2017-09-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02776761
The ClinicalTrials.gov registry entry for NCT02776761 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Hantaan Vaccine: is the first listed.
NCT02776761 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02776761 about?
NCT02776761 is a clinical study titled "A Single-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Hantaan Puumala Virus DNA Vaccine". This is a single-center, randomized, single-blinded study of the Hantaan virus HTNV DNA vaccine alone, Puumala virus PUUV DNA vaccine alone, and mixed Hantaan/Puumala HTNV/PUUV DNA vaccines delivered intramuscularly IM by the needle-free PharmaJet Stratus DSJI device.
What is the current status of trial NCT02776761?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2016-08-30. Estimated completion is 2017-09-27.
What interventions are being tested in trial NCT02776761?
The interventions under investigation include: Hantaan Vaccine: (BIOLOGICAL), Puumala Vaccine (BIOLOGICAL), Hantaan/Puumala Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02776761?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.